Ginkgo Bioworks — Third Quarter 2026 Earnings Summary

Ginkgo Bioworks reported third-quarter 2026 revenue of $28 million, a 6% decrease from the prior year, alongside a GAAP net loss of $41 million. The company highlighted the sale of its first autonomous lab to Novo, a top-tier pharmaceutical company, and secured new government contracts with ARPA-H and the NSF. Ginkgo maintains two core offerings, Autonomous Labs and Cloud Lab, which utilize the Nebula platform to provide onshore alternatives to overseas contract research organizations and generate AI training data. The company reaffirmed its full-year 2026 cash burn guidance of $125 to $150 million, with a cash balance of $285 million as of September 30, 2026.